LIZO 600

Broad Support Against Resistant Infections

10x1x10 Tablet

Pharma

Antibacterial

Product highlights

Next-generation oxazolidinone antibiotic
Effective against resistant Gram-positive organisms
100% oral bioavailability
Available in oral and IV formulations
Preferred choice in orthopedic and bone infections

Lizo 600 contains Linezolid 600 mg, an oxazolidinone antibiotic active against resistant Gram-positive bacteria including MRSA and VRE. It inhibits bacterial protein synthesis and provides reliable coverage in complicated infections.

Dosage Form

Tablets

Product Name

Lizo 600

Composition

Linezolid 600 mg Tablets

Therapeutic Segment

Antibiotics / Orthopedic & Critical Care Infections

Pharmacological Action

Broad-spectrum activity against resistant Gram-positive bacterial infections.

Mechanism

Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex required for bacterial growth.

Key Clinical Benefits

Strong activity against MDR Gram-positive organisms, Predictable pharmacokinetics, Smooth IV to oral switch therapy, Excellent tissue penetration, Supports management of severe bone and soft tissue infections

Key Indications

Complicated skin and soft tissue infections,
Hospital-acquired and community-acquired pneumonia,
Diabetic foot infections,
Bone and joint infections,
MRSA and VRE infections

Administration

To be administered orally as directed by the physician.

Recommended Usage

600 mg twice daily or as prescribed by the healthcare professional.

Dosage Form

Tablets

Product Name

Lizo 600

Composition

Linezolid 600 mg Tablets

Therapeutic Segment

Antibiotics / Orthopedic & Critical Care Infections

Pharmacological Action

Antibiotics / Orthopedic & Critical Care Infections

Mechanism

Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex required for bacterial growth.

Key Clinical Benefits

Key Indications